ISO 14708-4:2008

Implants for surgery - Active implantable medical devices - Part 4: Implantable infusion pumps

ISO 14708-4:2008 is applicable to active implantable medical devices intended to deliver medicinal substances to site-specific locations within the human body. ISO 14708-4:2008 is also applicable to some non-implantable parts and accessories of the devices. The tests that are specified in ISO 14708-4:2008 are type tests intended to be carried out on a sample of a device to show compliance, and are not intended to be used for the routine testing of manufactured products.

Implants chirurgicaux — Dispositifs médicaux implantables actifs — Partie 4: Pompes d'infusion en implant

General Information

• Status: Withdrawn
• Publication Date: 04-Nov-2008
• ICS: 11.040.40 - Implants for surgery, prosthetics and orthotics
• Technical Committee: ISO/TC 150/SC 6 - Active implants
• Drafting Committee: ISO/TC 150/SC 6/WG 4 - Implantable infusion pumps
• Current Stage: 9599 - Withdrawal of International Standard
• Start Date: 28-Feb-2022
• Completion Date: 13-Dec-2025

Relations

• Revised: ISO 14708-4:2022 - Implants for surgery - Active implantable medical devices - Part 4: Implantable infusion pump systems
• Effective Date: 08-Apr-2017

Standards Content (Sample)

INTERNATIONAL ISO
STANDARD 14708-4
First edition
2008-11-15
Implants for surgery — Active
implantable medical devices —
Part 4:
Implantable infusion pumps
Implants chirurgicaux — Dispositifs médicaux implantables actifs —
Partie 4: Pompes d'infusion en implant

Reference number
©
ISO 2008
PDF disclaimer
This PDF file may contain embedded typefaces. In accordance with Adobe's licensing policy, this file may be printed or viewed but
shall not be edited unless the typefaces which are embedded are licensed to and installed on the computer performing the editing. In
downloading this file, parties accept therein the responsibility of not infringing Adobe's licensing policy. The ISO Central Secretariat
accepts no liability in this area.
Adobe is a trademark of Adobe Systems Incorporated.
Details of the software products used to create this PDF file can be found in the General Info relative to the file; the PDF-creation
parameters were optimized for printing. Every care has been taken to ensure that the file is suitable for use by ISO member bodies. In
the unlikely event that a problem relating to it is found, please inform the Central Secretariat at the address given below.

©  ISO 2008
All rights reserved. Unless otherwise specified, no part of this publication may be reproduced or utilized in any form or by any means,
electronic or mechanical, including photocopying and microfilm, without permission in writing from either ISO at the address below or
ISO's member body in the country of the requester.
ISO copyright office
Case postale 56 • CH-1211 Geneva 20
Tel. + 41 22 749 01 11
Fax + 41 22 749 09 47
E-mail [e-mail]
Web www.iso.org
Published in Switzerland
ii © ISO 2008 – All rights reserved

Contents Page
Foreword. v
Introduction . vi
1 Scope . 1
2 Normative references . 1
3 Terms and definitions. 2
4 Symbols and abbreviated terms . 3
5 General requirements for non-implantable parts . 3
6 Requirements for particular active implantable medical devices . 3
7 General arrangement of the packaging. 5
8 General markings for active implantable medical devices . 5
9 Markings on the sales packaging . 6
10 Construction of the sales packaging. 6
11 Markings on the sterile pack . 6
12 Construction of the non-reusable pack. 7
13 Markings on the active implantable medical device . 7
14 Protection from unintentional biological effects caused by the active implantable medical
device. 7
15 Protection from harm to the patient or user caused by external physical features of the
active implantable medical device. 8
16 Protection from harm to the patient caused by electricity. 8
17 Protection from harm to the patient caused by heat . 9
18 Protection from ionizing radiation released or emitted from the active implantable
medical device . 9
19 Protection from unintended effects caused by the device. 9
20 Protection of the device from damage caused by external defibrillators. 10
21 Protection of the device from changes caused by high-power electrical fields applied
directly to the patient. 10
22 Protection of the active implantable medical device from changes caused by
miscellaneous medical treatments . 10
23 Protection of the active implantable medical device from mechanical forces . 10
24 Protection of the active implantable medical device from damage caused by electrostatic
discharge . 11
25 Protection of the active implantable medical device from damage caused by atmospheric
pressure changes . 11
26 Protection of the active implantable medical device from damage caused by temperature
changes . 11
27 Protection of the active implantable medical device from electromagnetic non-ionizing
radiation. 11
28 Accompanying documentation. 17
[8]
Annex AA (informative) Relationship between the fundamental principles in ISO/TR 14283 and
the clauses of this part of ISO 14708 . 20
Annex BB (informative) Relationship between the clauses of this part of ISO 14708 and the
fundamental principles listed in Annex AA. 30
Annex CC (informative) Rationale. 32
Bibliography . 41

iv © ISO 2008 – All rights reserved

Foreword
ISO (the International Organization for Standardization) is a worldwide federation of national standards bodies
(ISO member bodies). The work of preparing International Standards is normally carried out through ISO
technical committees. Each member body interested in a subject for which a technical committee has been
established has the right to be represented on that committee. International organizations, governmental and
non-governmental, in liaison with ISO, also take part in the work. ISO collaborates closely with the
International Electrotechnical Commission (IEC) on all matters of electrotechnical standardization.
International Standards are drafted in accordance with the rules given in the ISO/IEC Directives, Part 2.
The main task of technical committees is to prepare International Standards. Draft International Standards
adopted by the technical committees are circulated to the member bodies for voting. Publication as an
International Standard requires approval by at least 75 % of the member bodies casting a vote.
Attention is drawn to the possibility that some of the elements of this document may be the subject of patent
rights. ISO shall not be held responsible for identifying any or all such patent rights.
ISO 14708-4 was prepared by Technical Committee ISO/TC 150, Implants for surgery, Subcommittee SC 6,
Active implants.
ISO 14708 consists of the following parts, under the general title Implants for surgery — Active implantable
medical devices:
⎯ Part 1: General requirements for safety, marking and for information to be provided by the manufacturer
⎯ Part 2: Cardiac pacemakers
⎯ Part 3: Implantable neurostimulators
⎯ Part 4: Implantable infusion pumps
Introduction
This part of ISO 14708 specifies particular requirements for active implantable medical devices intended to
deliver a medicinal substance to site-specific locations within the human body, to provide basic assurance of
safety for both patients and users. It amends and supplements ISO 14708-1:2000, hereinafter referred to as
ISO 14708-1. The requirements of this part of ISO 14708 take priority over those of ISO 14708-1.
An implantable infusion pump is a device that delivers either a constant flow rate or a variable flow rate from
which a medicinal substance is delivered via an implanted catheter to site-specific locations within the human
body. An external programmer might be used to adjust device parameters.
This part of ISO 14708 is relevant to all parts and accessories of implantable infusion pumps, including
catheters, refill kits, direct access port kits, programmers and related software. Not all parts or accessories
might be intended to be totally or partially implanted, but there is a need to specify some requirements of non-
implantable parts and accessories if they could affect the safety or performance intended by the manufacturer.
Requirements for physiologic sensing functions of implantable infusion pumps are not included in this edition
of this part of ISO 14708 but might be considered in future editions.
Within this part of ISO 14708 the following terms are used to amend and supplement ISO 14708-1:
“Replacement”: the clause of ISO 14708-1 is replaced completely by the text of this particular part of
ISO 14708.
“Addition”: the text of this particular part of ISO 14708 is additional to the requirements of ISO 14708-1.
“Amendment”: the clause of ISO 14708-1 is amended as indicated by the text of this particular part of
ISO 14708.
“Not used”: the clause of ISO 14708-1 is not applied in this particular part of ISO 14708.
Subclauses, figures, or tables that are additional to those of ISO 14708-1 are numbered starting from 101;
additional annexes are lettered AA, BB, etc.

vi © ISO 2008 – All rights reserved

INTERNATIONAL STANDARD ISO 14708-4:2008(E)

Implants for surgery — Active implantable medical devices —
Part 4:
Implantable infusion pumps
1 Scope
This part of ISO 14708 is applicable to active implantable medical devices intended to deliver medicinal
substances to site-specific locations within the human body.
This part of ISO 14708 is also applicable to some non-implantable parts and accessories of the devices as
defined in Clause 3.
The tests that are specified in this part of ISO 14708 are type tests intended to be carried out on a sample of a
device to show compliance, and are not intended to be used for the routine testing of manufactured products.
NOTE This part of ISO 14708 is not intended to apply to non-implantable infusion systems. However, it does apply to
devices intended to be used as trial systems because of their close affiliation with implantable infusion pumps.
2 Normative references
The following referenced documents are indispensable for the application of this document. For dated
references, only the edition cited applies. For undated references, the latest edition of the referenced
document (including any amendments) applies.
ISO 14708-1, Implants for surgery — Active implantable medical devices — Part 1: General requirements for
safety, marking and for information to be provided by the manufacturer
IEC 60601-1:2005, Medical electrical equipment — Part 1: General requirements for basic safety and
essential performance
IEC 60601-1-2:2007, Medical electrical equipment — Part 1-2: General requirements for basic safety and
essential performance — Collateral standard: Electromagnetic compatibility — Requirements and tests
IEC 61000-4-3:2002, Electromagnetic compatibility (EMC) — Part 4–3: Testing and measurement
techniques — Radiated, radio-frequency, electromagnetic field immunity test
ANSI/AAMI PC69:2000, Active implantable medical devices — Electromagnetic compatibility — EMC test
protocols for implantable cardiac pacemakers and implantable cardioverter defibrillators
3 Terms and definitions
For the purposes of this document, the terms and definitions given in ISO 14708-1 and the following apply.
3.101
implantable infusion pump
active implantable medical device intended for delivery of a medicinal substance to a specific location within
the human body
NOTE For purposes of this part of ISO 14708, an implantable infusion pump can be a single article, or a system
consisting of a set of components and accessories which interact to achieve the performance intended by the
manufacturer. Not all of these components or accessories might be required to be partially or totally implanted, e.g.
programmers and trial systems.
3.102
pump gear
implantable part of an implantable infusion pump containing the fluid reservoir, energy source and, in some
cases, control electronics
3.103
fluid path
internal surfaces of the implantable infusion pump which are in direct contact with a medicinal substance
3.104
outlet port
port where fluid enters the delivery catheter
3.105
refill access port
port allowing access to the fluid reservoir
3.106
direct access port
port allowing access to the delivery catheter
3.107
internal volume
fluid volume extending from the reservoir to the outlet port
3.108
reservoir volume
fluid volume of the reservoir that can be discharged while maintaining infusion accuracy within specifications
3.109
residual volume
fluid volume that cannot be removed from the pump gear
3.110
projected service life
period after implantation when the implantable infusion pump remains within stated specifications and
characteristics
3.111
stability interval
calculated maximum interval between two subsequent reservoir refills to assure stability of the medicinal
substance
3.112
infusion accuracy
how close the true (actual) infusion rate is to the specified rate
2 © ISO 2008 – All rights reserved

3.113
repeatability
value below which the absolute difference between two successive test results obtained with the same
implantable infusion pump with the same infusate under the same conditions can be expected to lie, with a
probability of 95 %
NOTE 1 A more qualitative way of looking at repeatability is the ability to consistently deliver the same results over time
(e.g. infusion rate). Repeatability is a metric independent of accuracy.
[9]
NOTE 2 A method for calculating repeatability is given in Annex B of ISO 11631:1998 .
3.114
minimum rate
lowest rate selectable by the user
3.115
intermediate rate
rate specified by the manufacturer as typical for the implantable infusion pump
NOTE The rate specified might depend on the application.
3.116
maximum rate
highest rate selectable by the user
3.117
bolus
discrete quantity of liquid that is delivered in a short time
3.118
essential performance
performance necessary to achieve freedom from unacceptable risk
NOTE For guidance on essential performance concepts see IEC 60601-1.
4 Symbols and abbreviated terms
This clause of ISO 14708-1 and the following applies.
DUT device under test
5 General requirements for non-implantable parts
This clause of ISO 14708-1 applies.
6 Requirements for particular active implantable medical devices
Additional subclauses:
6.101 Implantable infusion pump characteristics
The specifications and characteristics (e.g. infusion accuracy and repeatability) stated by the manufacturer in
the accompanying documentation (see 28.8) shall be maintained over the projected service life and over the
range of environmental conditions stated by the manufacturer.
NOTE 1 Minimum environmental conditions for atmospheric pressure are specified in Clause 25.
Infusion accuracy shall be stated for all selectable rates (including bolus rates) over a range of reservoir
volumes. Constant flow implantable infusion pump accuracy shall be stated for the specified infusion rate of
the pump over a range of reservoir volumes.
The manufacturer shall provide a plot of infusion accuracy versus reservoir volume. For variable rate pumps
the plot shall contain curves for minimum rate, maximum rate, and one or more intermediate rates.
The method of computing and determining the infusion accuracy shall be clearly stated in the accompanying
documentation. Environmental test conditions used to establish infusion accuracy shall also be stated.
NOTE 2 Accuracy is a commonly used term and might include the effects of systematic and random errors. Although it
is convenient to combine all these errors under the heading “accuracy”, it is still a qualitative term.
For all selectable infusion rates, the repeatability of the actual rate shall also be stated. The method of
computing and determining the stated repeatability shall be clearly described in the accompanying
documentation.
Compliance shall be confirmed by inspection of test procedures and results provided by the manufacturer,
supported by the manufacturer’s calculations as appropriate.
6.102 Septum puncture test
A septum that allows entry to an access port (e.g. refill port or direct access port), shall be able to withstand
repeated insertions of a hypodermic needle while maintaining the security of the fluid reservoir throughout the
projected service life.
⎯ Test: The DUT shall be conditioned at 37 °C ± 1 °C for not less than 12 h to achieve thermal equilibration.
Each implantable pump septum shall be punctured randomly using the needle specified by the
manufacturer for septum puncture and in accordance with the manufacturer’s instructions. The needle
used for septum puncture shall be replaced if damage to the needle or the needle’s tip is noted by the
operator. The needle shall completely penetrate the septum and care should be taken not to damage the
needle’s tip during the test. Puncturing shall be done using a straight-line motion parallel to the septum's
axial centre-line as shown in Figure 101.
Septum leakage shall be determined by immersing the test unit in a water bath at 37 °C ± 1 °C and
allowing the temperature of the assembly to stabilize for a minimum of 30 min. Leakage shall be
determined by air pressure applied slowly to a pressure of twice the pump’s maximum operating pressure
or a minimum or 276 kPa. The septum’s exposed surfaces shall be examined for air bubble leakage for
1 min.
Compliance shall be confirmed if the access port life conforms to the manufacturer’s specified limits. The
maximum number of punctures recommended by the manufacturer shall be stated (see 28.8).

4 © ISO 2008 – All rights reserved

Key
1 needle
2 septum
Figure 101 — Septum puncture test
7 General arrangement of the packaging
This clause of ISO 14708-1 applies.
8 General markings for active implantable medical devices
This clause of ISO 14708-1 applies except as follows:
Additional subclauses:
8.101 If special handling measures have to be taken during transport, the transport packaging shall be
[1] [2]
marked accordingly (see for example ISO 780 or ISO 15223 ).
Compliance shall be checked by inspection.
8.102 The permissible environmental conditions for transport shall be marked on the outside of the
transport packaging.
Compliance shall be checked by inspection.
9 Markings on the sales packaging
This clause of ISO 14708-1 applies except as follows:
9.4
Addition:
Specific additional information shall be provided for the following components:
a) Pump gear
⎯ reservoir volume;
⎯ infusion flow rate for constant flow pump;
⎯ any additional information and relevant characteristics, as necessary, to identify the device.
b) Catheter
⎯ length (in centimetres);
⎯ any additional information and relevant characteristics, as necessary, to identify the device.
c) Refill kit
⎯ any information and relevant characteristics, as necessary, to identify the device.
d) Direct access port kit
⎯ any information and relevant characteristics, as necessary, to identify the device.
10 Construction of the sales packaging
This clause of ISO 14708-1 applies except as follows:
10.3
Amendment:
The test is replaced by 7.1.3 b) of IEC 60601-1:2005.
NOTE Removable stickers (e.g. temporary stickers used in the manufacturing process) that provide supplementary
information exceeding the information specified in Clause 9, need not be subjected to this test.
11 Markings on the sterile pack
This clause of ISO 14708-1 applies except as follows.
Additional subclause:
11.101 The sterile pack shall bear specific additional information for the following components:
a) Pump gear
⎯ reservoir volume;
⎯ infusion flow rate for constant flow pumps;
⎯ any additional information and relevant characteristics, as necessary, to identify the device.
6 © ISO 2008 – All rights reserved

b) Catheter
⎯ length (in centimetres);
⎯ any additional information and relevant characteristics, as necessary, to identify the device.
c) Refill kit
⎯ any additional information and relevant characteristics, as necessary to identify the device.
d) Direct access port kit
⎯ any additional information and relevant characteristics, as necessary to identify the device.
Compliance shall be checked by inspection.
12 Construction of the non-reusable pack
This clause of ISO 14708-1 applies.
13 Markings on the active implantable medical device
This clause of ISO 14708-1 applies except as follows:
13.1
Amendment:
The wet rub test is replaced by 7.1.3 b) of IEC 60601-1:2005, after which the markings shall remain clearly
legible.
14 Protection from unintentional biological effects caused by the active implantable
medical device
This clause of ISO 14708-1 applies except as follows:
14.2
Replacement:
Any part of the implantable infusion pump, intended in normal use to be in contact with body fluids, shall be
evaluated to determine if the release of particulate matter is hazardous.
⎯ Test: Remove the implantable part aseptically from the non-reusable pack. Immerse the implantable part
in a bath of approximately 9 g/l saline solution, suitable for injection, or filtered saline or ultra-pure water,
in a neutral glass container. The volume of the saline in millilitres shall be 5 ± 0,5 × the numerical value of
the surface area of the implantable part expressed in cm . The container shall be covered with a glass lid
and maintained at 37 °C ± 1 °C for between 8 h and 18 h, the bath being agitated throughout the period.
A reference sample of similar volume shall be prepared from the same batch of saline, maintained and
agitated in a similar way to the specimen. A sample of liquid from the specimen bath and from the
reference bath shall be compared using apparatus suitable for measurement of particle size, such as
apparatus operating on the light blockage principal [see for example method 2.9.19 of the European
[3]
Pharmacopoeia, 3rd edition, 1977, (Council of Europe) ].
The excess average count of particles from the specimen compared to the reference sample shall not exceed
the amount determined, by the manufacturer, to be hazardous. If the manufacturer does not make this
determination then the excess average count shall not exceed 100 per ml greater than 5,0 µm and shall not
exceed 5 per ml greater than 25 µm.
Compliance shall be confirmed by inspection of a design analysis provided by the manufacturer, supported by
the manufacturer’s calculations and data from test studies as appropriate.
14.3
Addition:
This requirement also applies to the implantable infusion pump’s fluid path materials (indirect contact).
[4]
Biocompatibility may be assessed in accordance with one or more parts of ISO 10993, e.g. ISO 10993-1 .
Additional subclause:
14.101
For implantable infusion pumps that require the medicinal substance to be periodically replenished, the
manufacturer shall establish the maximum interval during which the medicinal substance will maintain a
potency of at least 90 % of the initial concentration of the medicinal substance instilled into the pump’s
reservoir. The manufacturer shall stipulate the stability interval at body temperature for each medicinal
substance claimed (see 28.8). In addition, an evaluation for the presence of potentially hazardous degradation
products in the medicinal substance, for the stability interval established, shall be conducted.
Compliance shall be confirmed if records provided by the manufacturer establish that the safety and quality of
the substance have been verified by analogy with the appropriate methods.
15 Protection from harm to the patient or user caused by external physical features
of the active implantable medical device
This clause of ISO 14708-1 applies except as follows:
15.1
Amendment:
Clause 23 of IEC 60601-1:1988 is replaced by 9.3 of IEC 60601-1:2005 (see Clause 5).
Compliance shall be checked as specified in IEC 60601-1.
16 Protection from harm to the patient caused by electricity
This clause of ISO 14708-1 applies except as follows:
16.1
Amendment:
Clause 19 of IEC 60601-1:1988 is replaced by 8.7 of IEC 60601-1:2005 (see Clause 5).
16.2
Addition:
If the results of a risk assessment or other means (e.g. published data, test studies, calculations) indicate that
the current limit should be less than 1 µA for a particular application, then the allowable limit shall be changed
so that the risk is mitigated.
8 © ISO 2008 – All rights reserved

17 Protection from harm to the patient caused by heat
Replacement:
No outer surface of an implantable part of the implantable infusion pump shall be greater than 2 °C above the
normal surrounding body temperature, in normal operation or single-fault condition, unless the manufacturer
demonstrates that a higher temperature rise is justified for a particular application.
Compliance shall be confirmed by a review of the manufacturer’s documentation, including results from
modelling, a design or risk assessment, test studies or other appropriate means.
NOTE Currently, some studies have shown that, depending on the location of specific tissue within the human body,
a 2 °C temperature limit might be unnecessarily restrictive. Under this circumstance, the manufacturer is allowed the
burden of substantiation.
18 Protection from ionizing radiation released or emitted from the active implantable
medical device
This clause of ISO 14708-1 applies.
19 Protection from unintended effects caused by the device
This clause of ISO 14708-1 applies except as follows:
19.2
Replacement:
If the service life (see 3.110) of the implantable infusion pump is dependent upon an implanted source of
electrical energy, such as a battery, an indication shall be provided that gives an advanced notice of energy
source depletion. The manufacturer shall define the expected duration of the remaining service life following
this notice.
Compliance shall be confirmed by inspection of a design analysis provided by the manufacturer, supported by
the manufacturer’s calculations and data from test studies as appropriate.
NOTE This subclause is also applicable to rechargeable energy sources.
19.3
Replacement:
An implantable infusion pump shall be designed so that the failure of any single component, part or (if the
device incorporates a programmable electronic system) software program, shall not cause an unacceptable
hazard.
⎯ Assessment: Risk assessment and risk control shall be conducted in accordance with published
[5]
standards, such as ISO 14971 .
Compliance shall be confirmed by a review of the risk management report or equivalent manufacturer’s
documents.
19.4
Amendment:
The assessment is amended to allow clinical investigations conducted in accordance with published standards,
[6],[7]
such as ISO 14155-1 or 14155-2 .
Additional subclause:
19.101 The projected service life for a variable rate implantable infusion pump containing an implanted
electrical energy source shall be determined for a range of infusion rates including, but not limited to, various
daily infusion volumes when delivered as a continuous infusion. Short-term infusion rates that exceed typical
therapeutic infusion rates, but do not appreciably affect device longevity, are excluded from projected service
life calculations (see 28.19).
Compliance shall be confirmed by inspection of a design analysis provided by the manufacturer, supported by
the manufacturer’s calculations and data from test studies as appropriate.
20 Protection of the device from damage caused by external defibrillators
This clause of ISO 14708-1 applies.
21 Protection of the device from changes caused by high-power electrical fields
applied directly to the patient
This clause of ISO 14708-1 applies.
22 Protection of the active implantable medical device from changes caused by
miscellaneous medical treatments
Addition:
Other treatments and procedures, such as (but not limited to) MRI, PET and lithotripsy, shall also be
considered.
23 Protection of the active implantable medical device from mechanical forces
This clause of ISO 14708-1 applies except as follows:
23.1
Replacement:
Non-implantable parts of an implantable infusion pump shall comply with 15.3 of IEC 60601-1:2005
(see Clause 5). The number of drops for patient-carried parts that are hand-held shall be three from each of
three different starting orientations encountered during normal use (see 15.3.4.1 of IEC 60601-1:2005).
Compliance shall be checked as specified in IEC 60601-1.
23.2
Amendment:
The pump gear shall be constructed to withstand the mechanical forces that might occur during normal
conditions of use.
a) test frequency range: 5 Hz to 500 Hz;
2 2
b) acceleration spectral density: 0,7 (m/s ) /Hz;
c) shape of acceleration spectral density curve: flat horizontal, 5 Hz to 500 Hz;
d) duration of testing: 30 min in each of three mutually perpendicular axes.
10 © ISO 2008 – All rights reserved

Compliance shall be confirmed if the pump gear conforms to the device specifications after performing the test
procedure.
24 Protection of the active implantable medical device from damage caused by
electrostatic discharge
Replacement:
Non-implantable parts of an implantable infusion pump shall comply with 6.2.2 of IEC 60601-1-2:2007
(see Clause 5).
Compliance shall be checked as specified in IEC 60601-1-2.
25 Protection of the active implantable medical device from damage caused by
atmospheric pressure changes
This clause of ISO 14708-1 applies.
26 Protection of the active implantable medical device from damage caused by
temperature changes
This clause of ISO 14708-1 applies except as follows:
26.1
Amendment:
Clause 42 of IEC 60601-1:1998 is replaced by 11.1 of IEC 60601-1:2005 (see Clause 5).
27 Protection of the active implantable medical device from electromagnetic non-
ionizing radiation
Replacement:
27.101 Immunity
Implantable parts of the implantable infusion pump shall not cause any harm because of susceptibility to
electrical influences due to external electromagnetic fields, whether through malfunction of the device,
damage to the device, heating of the device or by causing local increase of induced electrical current density
within the patient.
Compliance shall be confirmed by review of test results and documentation, prepared by the manufacturer, for
the tests in 27.103 to 27.106.
27.102 General test conditions
a) Operating mode
During immunity testing, each function of the implantable infusion pump that is associated with essential
performance shall be tested in a mode that is most critical from a patient outcome perspective, based on a risk
analysis. The test documentation shall state the function and mode used.
NOTE 1 For example, essential performance could be related to infusate delivery accuracy and repeatability. A
variable rate pump can have several modes of operation (e.g. continuous infusion) and it might be appropriate to test more
than one.
NOTE 2 Infusion rates selected for the test could be related to typical use, such as intermediate rates. These are
especially appropriate if pump reaction to the immunity tests is unrelated to rate. A higher infusion rate will make it easier
to spot changes in infusate delivery. The rate selected has to be appropriate for the test dwell time duration. Catheter
length that determines rate for a constant flow pump has no bearing on immunity performance but needs to be long
enough to support the test setup
b) Performance criteria
Under the test conditions specified in Clause 27, each function of the implantable infusion pump that is tested
(see 27.102 a)) shall be evaluated for general performance using the appropriate criteria stated in Table 101.
If DUT performance satisfies the criteria stated, then compliance with the requirements of the test(s) is,
consequentially, achieved. For criteria B, performance degradation, loss of function, or unintentional
responses are allowed if no unacceptable risk is created.
NOTE A risk assessment can demonstrate that a hazard, created as a result of performance degradation, loss of
function or an unintentional response, does not result in an unacceptable risk.
The following degradations are not allowed:
⎯ component failures;
⎯ changes in programmable parameter settings;
⎯ reset to factory defaults;
⎯ change of operating mode;
⎯ false alarms;
⎯ initiation of any unintended operation.
Table 101 — General performance criteria of the DUT for the immunity tests in Clause 27
Criterion During test After test Test summary
A Operate as intended Operate as intended 27.103 – 1 mT level
No loss of function No loss of function 27,104 – A-line
No unintentional responses No degradation of performance 27.105 – 16 V/m
Conforms to device specs 27.106 – 40 mW
B Allowed if no unacceptable risk: Operate as intended 27.103 – 50 mT level
Performance degradation No loss of function 27.104 – B-line
Loss of function No degradation of performance 27.105 – 140 V/m
Unintentional responses Conforms to device specs
Lost functions shall be self-
recoverable
C Manufacturer defined Manufacturer defined 27.106 – optional levels

Test documentation shall include the details of the performance criteria used, a description of the methods
used to verify performance, justification for any allowances of this subclause used, and a report of the test
results indicating DUT performance as it pertains to criterion A, B, or C.
12 © ISO 2008 – All rights reserved

Electromagnetic interference that the patient should avoid or be aware of, as a result of DUT performance
during these immunity tests, shall be described in the accompanying documentation (see 28.22).
c) DUT configuration
Prior to each test, fill the pump reservoir with a suitable fluid (coloured fluid is easier to monitor) for
delivery into a container during the test. The fluid delivered from the catheter is monitored to evaluate the
performance of the DUT.
Fluid volume and, if appropriate, catheter size and length, shall be sufficient to maintain operating mode
[see 27.102 a)] for the duration of each test.
The DUT shall consist of the pump gear and any other implantable part necessary for it to achieve its
intended function.
Test documentation shall describe the DUT configuration and environmental conditions affecting the test
(e.g. temperature and pressure).
d) Testing of normally non-observable functions
If the operation of a function to be tested [see 27.102 a)] cannot normally be observed or verified during
the test, a method shall be provided for determining performance. The use of special hardware or
software might be necessary.
It is preferable to verify the operation of a function during the test, and this should be attempted. If this is
not possible then verification (of performance during the test) may be performed ex post facto.
e) Implantable infusion pumps that use wireless telemetry
For a wireless telemetry function tested to satisfy the requirements of 27.102 a), criterion B shall apply in
an exclusion band. All other functions shall comply with the requirements as stated.
The exclusion band shall not be larger than normally required for the telemetry function to operate as
intended.
f) Implantable infusion pumps without an electrical function
For infusion pumps without an electrical function (e.g. a pressure activated constant flow pump that does
not rely on electricity for part of its function) the tests in 27.104, 27.105 and 27.106 do not apply.
27.103 Protection from static magnetic fields
The assessment of the implantable infusion pump for static magnetic fields is made by exposure of the DUT to
two levels of static (non-time varying) fields.
⎯ Test: General test conditions are described in 27.102.
Test levels: Two test field strengths are used, applying different performance criteria to each. A lower level of
1 mT shall be subjected to the DUT, applying performance criterion A, as stated in 27.102 b). A second level
of 50 mT shall be used, applying performance criterion B.
Test setup: The apparatus for generating the magnetic field shall be capable of producing a field with
uniformity of dB over an area of radius 7,5 cm (minimum) that lies on a plane parallel to the apparatus.
+ 3
This plane shall be called the central plane. The uniformity of the magnetic field is only prescribed over the
central plane, which contains an imaginary Y and Z axis. Uniformity is not prescribed in the X+ or X− direction,
which represents the imaginary, perpendicular, axis running through the centre of the plane of the apparatus
and the central plane.
For most test configurations [see 27.102 c)] a uniform area of radius 7,5 cm will be large enough to cover the
DUT. If not, the uniform area shall be increased until it meets the requirements of this subclause.
Place the DUT at the centre of the central plane where the magnetic field is the most uniform. The plane of the
largest surface area of the DUT is placed parallel to the central plane (this exposes the pump’s largest surface
to the primary magnetic flux lines which are perpendicular to the central plane). This is the only orientation of
the DUT that is required.
The catheter will need to be placed in a position that facilitates monitoring of the fluid delivery during the test
(see 27.102). Any ancillary equipment that is needed to operate the pump or monitor its output during the test
shall, as much as possible, be selected and located to minimize disruption of the uniform field.
Test procedure: Monitor the performance of the DUT for a minimum of 10 min at each test level.
Evaluation of test results: Performance criterion A (1 mT) and performance criterion B (50 mT), as stated in
27.102 b), shall apply.
27.104 Protection from magnetic fields in the range 10 Hz to 30 MHz
The assessment of the implantable infusion pump for the range of frequencies from 10 Hz to 30 MHz is made
by exposure of the DUT to continuous wave and pulsed magnetic fields.
⎯ Test: General test conditions are described in 27.102.
Test levels: Magnetic field test levels are shown graphically in Figure 102 (values are A/m rms). Test levels
vary depending on frequency and performance criteria [see 27.102 b)]. The solid line in the figure represents
test levels that are subjected to the DUT, applying performance criterion A, as stated in 27.102 b). The dashed
line represents test levels applying performance criterion B. These shall be referred to as A-line and the B-line,
respectively, throughout this subclause. Both sets of test levels shall be applied to the DUT.
1 000
0,1
0,01
0,01 0,1 1 10 100 1 000 10 000 100 000
f (kHz)
Key
1 A-line (test levels, performance criterion A)
2 B-line (test levels, performance criterion B)
Figure 102 — Magnetic field test levels (RMS)
Test levels as a function of frequency are indicated numerically in Table 102.
14 © ISO 2008 – All rights reserved

H (A/m)
Table 102 — Magnetic field test levels (RMS)
Frequency range Field strengths for A-line Field strengths for B-line
kHz
H-field B-field H-field B-field
A/m µT A/m µT
0,01 – 0,06 795 1 000 ― ―
0,06 – 0,3 47,7/f 60/f ― ―
0,3 – 3,0 47,7/f 60/f 159 200
3,0 – 100 15,9 20 159 200
100 – 30 000 1 590/f 2 000/f 15 900/f 20 000/f
NOTE f is the frequency in kHz. All field levels are root-mean square (RMS).

Test set-up: The test coil(s) for generating the magnetic field shall be capable of producing a field with
uniformity as specified in Table 103. The uniform field shall exist over an area of radius 7,5 cm (minimum) that
lies on a plane parallel to the coil(s). This plane shall be called the central plane. The uniformity of the
magnetic field is only prescribed over the central plane, which contains an imaginary Y and Z axis. Uniformity
is not prescribed in the X+ or X− direction, which represents the imaginary, perpendicular, axis running
through the centre of the plane of the coils and the central plane.
For most test configurations [see 27.102 c)] a uniform area of radius 7,5 cm will be large enough to cover the
DUT. If not, the uniform area shall be increased until it meets the requirements of this subclause.
Table 103 — Magnetic field uniformity
A-line B-line
f u 100 kHz, dB
+1
300 Hz u f u 30 MHz, dB
+ 3
f > 100 kHz, dB
+ 3
NOTE f is the test frequency.
Place the DUT into a saline bath of 0,27 S/m conductivity (equivalent to 370 Ω cm volume resistivity) at the
centre of the central plane where the magnetic field is the most uniform. The
...